Literature DB >> 33556173

Anti-PD-1 plus anti-VEGF therapy in multiple intracranial metastases of a hypermutated, IDH wild-type glioblastoma.

Xiaopeng Guo1, Shishuai Wang1, Yu Wang1, Wenbin Ma1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33556173      PMCID： PMC8041397          DOI： 10.1093/neuonc/noab005

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  6 in total

1.  Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis.

Authors:  E Zeynep Erson-Omay; Ahmet Okay Çağlayan; Nikolaus Schultz; Nils Weinhold; S Bülent Omay; Koray Özduman; Yavuz Köksal; Jie Li; Akdes Serin Harmancı; Victoria Clark; Geneive Carrión-Grant; Jacob Baranoski; Caner Çağlar; Tanyeri Barak; Süleyman Coşkun; Burçin Baran; Doğan Köse; Jia Sun; Mehmet Bakırcıoğlu; Jennifer Moliterno Günel; M Necmettin Pamir; Ketu Mishra-Gorur; Kaya Bilguvar; Katsuhito Yasuno; Alexander Vortmeyer; Anita J Huttner; Chris Sander; Murat Günel
Journal:  Neuro Oncol       Date:  2015-03-03       Impact factor: 12.300

2.  Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.

Authors:  Rimas V Lukas; Jordi Rodon; Kevin Becker; Eric T Wong; Kent Shih; Mehdi Touat; Marcella Fassò; Stuart Osborne; Luciana Molinero; Carol O'Hear; William Grossman; Joachim Baehring
Journal:  J Neurooncol       Date:  2018-08-02       Impact factor: 4.130

3.  Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.

Authors:  Tanner M Johanns; Christopher A Miller; Ian G Dorward; Christina Tsien; Edward Chang; Arie Perry; Ravindra Uppaluri; Cole Ferguson; Robert E Schmidt; Sonika Dahiya; George Ansstas; Elaine R Mardis; Gavin P Dunn
Journal:  Cancer Discov       Date:  2016-09-28       Impact factor: 39.397

4.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

Authors:  Eric Bouffet; Valérie Larouche; Brittany B Campbell; Daniele Merico; Richard de Borja; Melyssa Aronson; Carol Durno; Joerg Krueger; Vanja Cabric; Vijay Ramaswamy; Nataliya Zhukova; Gary Mason; Roula Farah; Samina Afzal; Michal Yalon; Gideon Rechavi; Vanan Magimairajan; Michael F Walsh; Shlomi Constantini; Rina Dvir; Ronit Elhasid; Alyssa Reddy; Michael Osborn; Michael Sullivan; Jordan Hansford; Andrew Dodgshun; Nancy Klauber-Demore; Lindsay Peterson; Sunil Patel; Scott Lindhorst; Jeffrey Atkinson; Zane Cohen; Rachel Laframboise; Peter Dirks; Michael Taylor; David Malkin; Steffen Albrecht; Roy W R Dudley; Nada Jabado; Cynthia E Hawkins; Adam Shlien; Uri Tabori
Journal:  J Clin Oncol       Date:  2016-03-21       Impact factor: 44.544

5.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Authors:  Timothy F Cloughesy; Aaron Y Mochizuki; Joey R Orpilla; Willy Hugo; Alexander H Lee; Tom B Davidson; Anthony C Wang; Benjamin M Ellingson; Julie A Rytlewski; Catherine M Sanders; Eric S Kawaguchi; Lin Du; Gang Li; William H Yong; Sarah C Gaffey; Adam L Cohen; Ingo K Mellinghoff; Eudocia Q Lee; David A Reardon; Barbara J O'Brien; Nicholas A Butowski; Phioanh L Nghiemphu; Jennifer L Clarke; Isabel C Arrillaga-Romany; Howard Colman; Thomas J Kaley; John F de Groot; Linda M Liau; Patrick Y Wen; Robert M Prins
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440

6.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.

Authors:  David A Reardon; Alba A Brandes; Antonio Omuro; Paul Mulholland; Michael Lim; Antje Wick; Joachim Baehring; Manmeet S Ahluwalia; Patrick Roth; Oliver Bähr; Surasak Phuphanich; Juan Manuel Sepulveda; Paul De Souza; Solmaz Sahebjam; Michael Carleton; Kay Tatsuoka; Corina Taitt; Ricardo Zwirtes; John Sampson; Michael Weller
Journal:  JAMA Oncol       Date:  2020-07-01       Impact factor: 31.777
  6 in total
  4 in total

1.  Glioblastoma Embryonic-like Stem Cells Exhibit Immune-Evasive Phenotype.

Authors:  Borja Sesé; Sandra Íñiguez-Muñoz; Miquel Ensenyat-Mendez; Pere Llinàs-Arias; Guillem Ramis; Javier I J Orozco; Silvia Fernández de Mattos; Priam Villalonga; Diego M Marzese
Journal:  Cancers (Basel)       Date:  2022-04-21       Impact factor: 6.575

2.  A rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy.

Authors:  Jia-Li Zhao; Jing Liu; Ming Fang; Chen Luo; Zhen-Bang Gu; Long Huang
Journal:  BMC Neurol       Date:  2022-10-22       Impact factor: 2.903

3.  Treatment of MGMT promoter unmethylated glioblastoma with PD-1 inhibitor combined with anti-angiogenesis and epidermal growth factor receptor tyrosine kinase inhibitor: a case report.

Authors:  Zheng Wang; Fangfang Du; Yi Ren; Wei Jiang
Journal:  Ann Transl Med       Date:  2021-10

4.  Immune checkpoint inhibitor in recurrent hypermutated glioblastoma with POLE mutation.

Authors:  Sith Sathornsumetee; Sarun Nunta-Aree; Pornsuk Cheunsuchon
Journal:  Neurooncol Adv       Date:  2021-06-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.